aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin]
- RxCUI
- 211292
- RxNorm name
- aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin]
- Display name
- ANACIN (Oral Pill)
- Full name
- aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin]
- Term type
- SBD
- Status
- Active
- Strength
- 400-32 mg
- Dose form
- Tab
- Route
- Oral Pill
- Updated
- 2026-11-12 19:37:03
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 042005
- Active start
- 042005
- Multiple ingredient
- YES
- Branded
- YES
Ingredients And Strength#
Dose Form Concepts#
| Dose form | RxCUI |
|---|---|
| Oral Tablet | 317541 |
Derived Ingredient Concepts#
Source Vocabulary Codes#
| Code type | Values | Count | Category |
|---|---|---|---|
| PRESCRIBABLE | Y | 1 | ATTRIBUTES |
| RXNAV_STR | ASA 400 MG / Caffeine 32 MG Oral Tablet [Anacin] | 1 | NAMES |
| RxNorm Name | aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin] | 1 | NAMES |
| RxNorm Synonym | 2 | NAMES | |
| TTY | SBD | 1 | ATTRIBUTES |
| SPL_SET_ID | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 1 | CODES |
| RxCUI | 211292 | 1 | CODES |
| MMSL_CODE | BD4946 | 1 | CODES |
FDA NDC Products And Packages#
| Package NDC | Product NDC | Name | Labeler | Application |
|---|---|---|---|---|
| 63736-200-90 | 63736-200 | Anacin Asprin and Caffeine | Insight Pharmaceuticals LLC | M013 |
| 63736-200-93 | 63736-200 | Anacin Asprin and Caffeine | Insight Pharmaceuticals LLC | M013 |
Drugs@FDA Applications#
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anacin | ASPRIN AND CAFFEINE | Insight Pharmaceuticals LLC | 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | 2025-10-23 | Warnings | 63736-200-90 63736-200-93 63736-200 63736020030 63736020090 63736020091 63736020093 63736020050 63736020092 63736020004 63736020095 211292 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
| Set ID | RxNorm mappings | Terms | SPL version | Label | Effective |
|---|---|---|---|---|---|
| 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | ANACIN 400 MG / 32 MG Oral Tablet [PSN] · aspirin 400 MG / caffeine 32 MG Oral Tablet [Anacin] [SBD] · Anacin (ASA 400 MG / caffeine 32 MG) Oral Tablet [SY] · ASA 400 MG / Caffeine 32 MG Oral Tablet [Anacin] [SY] | 4 | 9 | Anacin - 63736-200 | 20251023 |
Recently Linked DailyMed Labels#
| Set ID | Title | Manufacturer | Effective |
|---|---|---|---|
| 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | Anacin - 63736-200 | Insight Pharmaceuticals LLC | 20251023 |
| 51ab0ee3-3c94-424d-a30a-2d6c14e3d8ff | Anacin - 63736-200 | Insight Pharmaceuticals LLC | 20250116 |
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | A01AD | Other agents for local oral treatment | ATC1-4 | aspirin | |
| ATC | D11AX | Other dermatologicals | ATC1-4 | caffeine | |
| ATC | B01AC | Platelet aggregation inhibitors excl. heparin | ATC1-4 | aspirin | |
| ATC | N02BA | Salicylic acid and derivatives | ATC1-4 | aspirin | |
| ATC | N06BC | Xanthine derivatives | ATC1-4 | caffeine | |
| FDASPL | N0000175739 | Central Nervous System Stimulant | EPC | has_epc | caffeine |
| FDASPL | N0000175790 | Methylxanthine | EPC | has_epc | caffeine |
| FDASPL | N0000175722 | Nonsteroidal Anti-inflammatory Drug | EPC | has_epc | aspirin |
| FDASPL | N0000175578 | Platelet Aggregation Inhibitor | EPC | has_epc | aspirin |
| MEDRT | D001241 | Aspirin | CHEM | has_ingredient | aspirin |
| MEDRT | D002110 | Caffeine | CHEM | has_ingredient | caffeine |
| MEDRT | D001049 | Apnea | DISEASE | may_treat | caffeine |
| MEDRT | D001172 | Arthritis, Rheumatoid | DISEASE | may_treat | aspirin |
| MEDRT | D001778 | Blood Coagulation Disorders | DISEASE | ci_with | aspirin |
| MEDRT | D001791 | Blood Platelet Disorders | DISEASE | ci_with | aspirin |
| MEDRT | D002544 | Cerebral Infarction | DISEASE | may_prevent | aspirin |
| MEDRT | D002644 | Chickenpox | DISEASE | ci_with | aspirin |
| MEDRT | D002675 | Child, Preschool | DISEASE | ci_with | aspirin |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | aspirin |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | caffeine |
| MEDRT | D005221 | Fatigue | DISEASE | may_treat | caffeine |
| MEDRT | D005334 | Fever | DISEASE | may_treat | aspirin |
| MEDRT | D006073 | Gout | DISEASE | may_treat | aspirin |
| MEDRT | D006396 | Hematemesis | DISEASE | ci_with | aspirin |
| MEDRT | D006474 | Hemorrhagic Disorders | DISEASE | ci_with | aspirin |
| MEDRT | D007223 | Infant | DISEASE | ci_with | aspirin |
| MEDRT | D007249 | Inflammation | DISEASE | may_treat | aspirin |
| MEDRT | D002546 | Ischemic Attack, Transient | DISEASE | may_prevent | aspirin |
| MEDRT | D008551 | Melena | DISEASE | ci_with | aspirin |
| MEDRT | D009203 | Myocardial Infarction | DISEASE | may_prevent | aspirin |
| MEDRT | D009298 | Nasal Polyps | DISEASE | ci_with | aspirin |
| MEDRT | D010003 | Osteoarthritis | DISEASE | may_treat | aspirin |
| MEDRT | D010146 | Pain | DISEASE | may_treat | aspirin |
| MEDRT | D010146 | Pain | DISEASE | may_prevent | aspirin |
| MEDRT | D011225 | Pre-Eclampsia | DISEASE | may_prevent | aspirin |
| MEDRT | D011263 | Pregnancy Trimester, Third | DISEASE | ci_with | aspirin |
| MEDRT | D012213 | Rheumatic Fever | DISEASE | may_treat | aspirin |
| MEDRT | N0000000160 | Cyclooxygenase Inhibitors | MOA | has_moa | aspirin |
| MEDRT | N0000000133 | Enzyme Inhibitors | MOA | has_moa | caffeine |
| MEDRT | N0000008322 | Bronchodilation | PE | has_pe | caffeine |
| MEDRT | N0000008331 | Cardiovascular Activity Alteration | PE | has_pe | caffeine |
| MEDRT | N0000008567 | Decreased Collecting Duct Water Permeability | PE | has_pe | caffeine |
| MEDRT | N0000008831 | Decreased Platelet Activating Factor Production | PE | has_pe | aspirin |
| MEDRT | N0000008832 | Decreased Platelet Aggregation | PE | has_pe | aspirin |
| MEDRT | N0000008836 | Decreased Prostaglandin Production | PE | has_pe | aspirin |
| MEDRT | N0000009006 | Decreased Thromboxane Production | PE | has_pe | aspirin |
| MEDRT | N0000009197 | Increased Central Nervous System Organized Electrical Activity | PE | has_pe | caffeine |
| MEDRT | N0000000026 | Hepatic Metabolism | PK | has_pk | aspirin |
| MEDRT | N0000000042 | Renal Excretion | PK | has_pk | aspirin |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | AVAILABLE_STRENGTH | 400 MG / 32 MG |
| ATTRIBUTES | GENERAL_CARDINALITY | MULTI |
| ATTRIBUTES | HUMAN_DRUG | US |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| ATTRIBUTES | SCHEDULE | 0 |
| NAMES | Prescribable Synonym | ANACIN 400 MG / 32 MG Oral Tablet |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Micromedex RED BOOK |
| SOURCES | Source | Multum MediSource Lexicon |